# Sagimet Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sagimet-biosciences

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.sagimet.com
- Total disclosed funding: $169M
- Latest round: Series F (Dec 21, 2020)
- Investors on record: 11

## About

Based in California, US, and founded in 2006, Sagimet Biosciences Inc. is a clinical-stage pharmaceutical company that develops novel therapeutics for the treatment of oncology like breast cancer, astrocytoma, colon cancer, and other infectious diseases such as non-alcoholic steatohepatitis (NASH). The company was founded by Lucas Pelkmans and Urs Greber. In February 2021, Sagimet Biosciences Inc. raised USD 80 million in venture funding from Altium Capital, Kleiner Perkins, and New Enterprise Associates.

The company offers TVB-2640, which targets and synthesizes fatty acid synthase (FASN). It also offers antiviral therapeutics for the respiratory syncytial virus (RSV), cytomegalovirus (CMV), and other human pathogens.

Sagimet Biosciences plans to advance its lead program, explore additional indications, and file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021.

## Funding rounds

- Series F, Dec 21, 2020, $69M — Kleiner Perkins, New Enterprise Associates, Invus [DUP], Altium Capital, Ascletis Pharma Inc., Rock Springs Capital, HM Capital, PFM Health Sciences
- Series E, Feb 12, 2019, $35M — Kleiner Perkins, New Enterprise Associates, Ascletis Pharma Inc., Qianhai Ark Capital
- Series D, Oct 22, 2014, $14M — Kleiner Perkins, New Enterprise Associates, Rock Springs Capital, Ally Bridge Group
- Series C, Jun 14, 2013, $7.5M — Kleiner Perkins, New Enterprise Associates
- Series B, Dec 19, 2012, $8.1M — Kleiner Perkins, New Enterprise Associates
- Series B, Nov 29, 2011, $12M — Kleiner Perkins, New Enterprise Associates
- Series B, Jul 7, 2009, $15M — Kleiner Perkins, New Enterprise Associates, The Column Group
- Series A, Apr 30, 2007, $7.6M — Kleiner Perkins, The Column Group

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B, Series C, Series D, Series E, Series F
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C, Series D, Series E, Series F
- Rock Springs Capital — Series D, Series F
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D
- Ascletis Pharma Inc. — Series E, Series F
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series E
- Invus [DUP] — Series F
- Altium Capital — Series F
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series F
- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Series F